DNAL1 peptide is used for blocking the activity of DNAL antibody. It usually blocks the antibody activity completely in Western blot by incubating the peptide with equal volume of antibody for 30 min at 37˚C.
DNAL1 was identified as a potential candidate gene for primary ciliary dyskinesia (PCD), a genetically heterologous disorder characterized by chronic infections of the upper and lower airways that often leads to permanent lung damage, randomization of left/right body symmetry, and reduced fertility. DNAL1 is reported to be expressed solely in tissues carrying motile cilia for flagella and interacts with DNAH5, a protein that when mutated has been shown to result in PCD. It has been suggested that DNAL1 serves a regulatory function for DNAH5 activity in outer dynein arms of sperm flagella, respiratory cilia, and ependymal cilia. DNAL1 has also been recently identified as an HIV dependency factor (HDF), suggesting that DNAL1 may be an important drug target in HIV treatment. At least two isoforms of DNAL1 are known to exist.
Source:Peptide corresponding to 17aa from near the carboxy terminus of human DNAL1.
Applications:Suitable for use in Western Blot. Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only. For long-term storage, aliquot and store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
仕様
Size：50ug
Grade：Purified
Purity：Purified
Form：Supplied as a liquid in PBS, pH 7.2 (10mm NaH2PO4, 10mm Na2HPO4, 130mm NaCl), 0.1% BSA, 0.02% sodium azide.
